We reviewed randomized trials of adult ICU patients of interventions hypothesized to reduce delirium burden to determine whether interventions that are more effective at reducing delirium duration are associated with a reduction in short-term mortality. Data Sources: We searched CINHAHL, EMBASE, MEDLINE, and the Cochrane databases from 2001 to 2012. Study Selection: Citations were screened for randomized trials that enrolled critically ill adults, evaluated delirium at least daily, compared a drug or nondrug intervention hypothesized to reduce delirium burden with standard care (or control), and reported delirium duration and/or short-term mortality (≤ 45 d). Data Extraction: In duplicate, we abstracted trial characteristics and results and evaluated quality using the Cochrane risk of bias tool. We performed random effects model meta-analyses and meta-regressions. Data Synthesis: We included 17 trials enrolling 2,849 patients which evaluated a pharmacologic intervention (n = 13) (dexmedetomidine [n = 6], an antipsychotic [n = 4], rivastigmine [n = 2], and clonidine [n = 1]), a multimodal intervention (n = 2) (spontaneous awakening [n = 2]), or a nonpharmacologic intervention (n = 2) (early mobilization [n = 1] and increased perfusion [n = 1]). Overall, average delirium duration was lower in the intervention groups (difference = -0.64 d; 95% CI, -1.15 to -0.13; p = 0.01) being reduced by more than or equal to 3 days in three studies, 0.1 to less than 3 days in six studies, 0 day in seven studies, and less than 0 day in one study. Across interventions, for 13 studies where short-term mortality was reported, short-term mortality was not reduced (risk ratio = 0.90; 95% CI, 0.76-1.06; p = 0.19). Across 13 studies that reported mortality, meta-regression revealed that delirium duration was not associated with reduced short-term mortality (p = 0.11). Conclusions: A review of current evidence fails to support that ICU interventions that reduce delirium duration reduce short-term mortality. Larger controlled studies are needed to establish this relationship. (Crit Care Med 2014; 42:1442-1454 
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For information regarding this article, E-mail: j.devlin@neu.edu Randomized ICU Trials Do Not Demonstrate an Association Between Interventions That Reduce Delirium Duration and Short-Term Mortality: A Systematic Review and Meta-Analysis* functional impairment (1) (2) (3) (4) . The "burden of delirium" in the critically ill can be quantified by its duration, severity or intensity, or as various delirium-associated complications. Among markers of delirium burden, delirium duration is the simplest and most reliable measure. Delirium severity scales require patients to communicate verbally (5) . Delirium screening tools are limited in their ability to evaluate delirium severity, assessment results may be confounded by concomitant conditions (e.g., level of sedation), and the longer term complications of delirium of greatest clinical relevance remain unclear (6) (7) (8) (9) (10) .
Mortality in the first month after ICU admission has been commonly used as an outcome to evaluate the efficacy and safety of interventions in the critically ill (11, 12) . A number of pharmacologic (e.g., antipsychotics and dexmedetomidine) and nonpharmacologic (e.g., early mobilization) interventions have been shown to reduce delirium burden in the critically ill (5, (13) (14) (15) . However, when evaluated in prospective, randomized studies, none of these interventions have been shown to reduce short-term mortality. Many studies were too small to detect a difference in short-term mortality or evaluated an ICU population with a low mortality rate (e.g., cardiac surgery) (14) .
Although the duration of Confusion Assessment for the ICU (CAM-ICU)-screened delirium has been associated independently with higher mortality in the critically ill (16) (17) (18) , it remains unclear if interventions that decrease delirium duration in the critically ill will also reduce short-term mortality (19) . Using the increased power of meta-analytic techniques, we sought to review published randomized trials to test the hypothesis that interventions that reduce the duration of delirium are associated with a reduction in short-term mortality.
METHODS

Trial Identification
An experienced medical librarian assisted our search for eligible studies using the following key words: "delirium" OR "brain dysfunction" AND "intensive care" OR "critical care" OR "ICU" AND "random*." We searched six databases (EMBASE, MEDLINE, CINAHL, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and http://www.ClinicalTrials.gov) for relevant trials from 2001 to December 2012. We reviewed personal files, reference lists of review articles, and reference lists in eligible studies for additional trials. In addition, we requested advice from experts in the field; searched abstract books from major critical care, surgical, and geriatric scientific meetings; and contacted investigators conducting randomized controlled trials (RCTs) in this area. We chose 2001 as the initial search year since two ICU delirium screening instruments with good psychometric strength, and frequently used in clinical practice, were published that year (i.e., CAM-ICU and the Intensive Care Delirium Screening Checklist, ICDSC) (5, 10, 20) . Non-English-language and gray literatures (unpublished, nonpeer-reviewed studies) were excluded. The Institutional Review Board (IRB) at Northeastern University waived the need for IRB approval.
Eligibility Criteria
We included randomized controlled parallel group or factorial trials of adults (≥ 19 yr or older) admitted to an ICU at the time of study randomization. We included any pharmacologic, nonpharmacologic, or mixed pharmacologic/nonpharmacologic strategy hypothesized to decrease delirium burden (i.e., delirium duration, delirium severity, or delirium-associated complications) with any other strategy. To be included, trials had to measure delirium at least once daily with a validated technique such as the CAM-ICU or ICDSC or have delirium assessed by a psychiatrist or neurologist using Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) criteria (10, 20, 21) . Ideally, trials reported both delirium duration and shortterm mortality (i.e., either at hospital discharge or 21, 28, 30, or 45 days after the time of study randomization).
Trial Selection
We screened abstracts and titles in duplicate for potentially relevant studies. These were rescreened in duplicate in full-text form. For articles that did not report either delirium duration or short-term mortality, we contacted the corresponding author to provide the missing outcome(s) or to confirm that these data were not collected during the study. Corresponding authors who failed to respond after the first contact were contacted two additional times over a 6-week period.
Data Abstraction and Risk of Bias Assessment
Using a custom-made data collection form, two reviewers independently abstracted data regarding the design, patient population, intervention and comparison, clinical outcomes, and methodological quality using the "risk of bias tool" recommended by the Cochrane Collaboration (22) . For each trial, risk of bias was evaluated for six domains (i.e., reporting, attrition, detection, performance, selection, and other [i.e., potential sources of bias not accounted for in the prior six domains]) and an "overall" risk of bias was estimated. For each domain, risk of bias was categorized as "low," "unclear," or "high." Disagreement for all methodological steps was resolved by discussion and consensus.
Data Synthesis
We separately analyzed differences in delirium duration (in days) and risk ratios (RRs) of short-term mortality across all studies with adequate data using random effects model meta-analyses. For the calculation of the mean difference in delirium duration, data on the means and se were required; these were estimated for studies reporting median and interquartile or full ranges if investigators did not report these values or respond to queries (23) . To assess the association between effect of an intervention on delirium duration and the short-term mortality, we attempted to run a multivariate random effects meta-analysis with the "mvmeta" function in Stata 11.2 (StataCorp, College Station, TX). However, since the algorithm failed to converge, except under infeasible assumptions about the within-study correlation between delirium duration and mortality (r > 0.95), we proceeded with a random effects model meta-regression of all studies where both duration of delirium and short-term mortality were reported. Meta-analyses and the meta-regression were conducted using the "metan" and "metareg" function in Stata 11.2. For each meta-analysis, we report the statistical significance of the chi-square test for heterogeneity and the I 2 statistic, which estimates the variation in the outcome attributable to heterogeneity rather than chance (24, 25) .
Sensitivity Analyses
To explore the clinical and statistical heterogeneity across the studies, we conducted six post hoc sensitivity analyses for delirium duration, short-term mortality, and the association between these two outcomes, to account for potential factors that we hypothesized could influence one or more of these outcomes/relationships: 1) the method of delirium assessment (i.e., CAM-ICU vs ICDSC) given evidence suggesting that the sensitivity and specificity of these two instruments may differ (5, 26, 27) ; 2) the predominate ICU service that the patient was admitted to (i.e., medical vs surgical); 3) the presence of delirium at the time of enrollment in some or all patients versus the presence of delirium in none; 4) patients at low risk for mortality (≤ 5%) versus those at high risk for mortality (≥ 10%); 5) patients administered a pharmacologic intervention versus those administered a nonpharmacologic intervention; and 6) among patients administered a pharmacologic intervention, those administered antipsychotic versus an α-2 receptor agonist (e.g., clonidine or dexmedetomidine) or an acetylcholinesterase inhibitor (e.g., rivastigmine). For each meta-analysis, we conducted meta-regressions including each of the sensitivity analysis factors as covariates evaluating the statistical significance of the interaction between each factor and the outcome. For example, we tested the interaction between the method of delirium assessment and delirium duration. We also conducted a sensitivity analysis of the meta-regression between delirium duration and death excluding any study where the duration of delirium was longer in the intervention than that in the control group.
RESULTS
Trial Identification
Our search yielded 145 publications (136 from the electronic database search and 9 from hand searching) ( Fig. 1) . We excluded 122 articles based on a review of the title and abstract; of 23 remaining studies, six were excluded during full review: neither delirium or short-term mortality was evaluated or reported (n = 4) (28-31); delirium was evaluated only once at the end of the study (n = 1) (32), and agitation, rather than delirium, was evaluated (n = 1) (33).
We included 17 randomized trials enrolling 2,849 patients in this systematic review (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) . Of these, four evaluated antipsychotic therapy (34-37); one evaluated IV clonidine (38) ; six evaluated dexmedetomidine (39) (40) (41) (42) (43) (44) ; two evaluated rivastigmine (45, 46) ; two evaluated daily sedative interruption (47, 50) ; one evaluated early mobilization after daily sedation interruption (48) ; and one evaluated the maintenance of a high perioperative perfusion pressure (49) . Table 1 describes the characteristics of the 17 studies (34-50). Eleven of the 17 studies were blinded (34) (35) (36) (37) (38) (39) (42) (43) (44) (45) (46) . Among the six unblinded studies (40, 41, (47) (48) (49) (50) , four evaluated a nonpharmacologic intervention that would be challenging to apply in a blinded fashion (47) (48) (49) (50) .
Trial Characteristics
Delirium was evaluated either by a member of the study's research team using the CAM-ICU (35, 37, 39, 43, (46) (47) (48) ; by bedside clinicians using either the CAM-ICU (42, 44, 45) or the ICDSC (34, 41, 50) ; by a psychiatrist using DSM-IV criteria (38, 40, 47) ; or the bedside clinician using the ICDSC with confirmation by a psychiatrist using DSM-IV criteria (36) . Duration of delirium was either not collected during the study or was not retrievable from two studies (43, 49) . Mortality was reported at hospital discharge for six studies (34, 36, 40, 44, 45, 50) and at poststudy randomization day 21 in two studies (35, 47) , day 28 in three studies (37, 39, 48) , day 30 in three studies (42, 46, 49) , or day 45 in one study (43) . Short-term mortality was not able to be determined from authors for two studies (38, 40) . Most of the studies (n = 14) had a low Cochrane risk of bias (34-39, 42, 44-50) (Supplemental Fig. 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/A844). Table 2 highlights the patient characteristics (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) . The studies enrolled either a mixed-medical-surgical population (n = 8) (34, 35, 39, 41-43, 46, 50) , a surgical population (n = 7) (36-38, 40, 45, 49) , or a medical population (n = 2) (47, 48) . Most of the studies (n = 13) enrolled only patients who were intubated (35, (38) (39) (40) (41) (42) (43) (44) (45) (47) (48) (49) (50) . The average patient age was older than 50 years across all intervention and control groups in all 17 studies. Where reported, the average Acute Physiology and Chronic Health Evaluation (APACHE) II score varied widely across the studies. In eight of the studies, all patients were delirium free at the time of study randomization (36-38, 40, 48, 49) and in two of the studies all patients had delirium at the time of randomization (34, 46) .
Duration of Delirium
All 17 trials reported duration of delirium (Fig. 2) . The average delirium duration (vs control) was reduced in the intervention groups (difference = -0.64 d; 95% CI, -1.15 to -0.13; p = 0.014) and was reduced on average more than or equal to 3 days for three studies, 0.1 to less than 3 days for six studies, 0 day for seven studies, and less than 0 day for one study. Across studies, there was a wide range of net effects on delirium duration, from a significant reduction by 3.4 days to a nonsignificant increase by 2.0 days. Consistent with the range of effects, the studies were significantly heterogeneous (p < 0.001); 71% of the differences are attributable to heterogeneity.
Short-Term Mortality
Thirteen trials reported short-term mortality (Fig. 3) . Across the studies, the short-term mortality rate was similar between the intervention (15.6%) and control groups (16.5%) (p = 0.54). Compared with control, the interventions had no significant effect on death (RR = 0.90; 95% CI, 0.76-1.06; p = 0.19). The studies were statistically homogeneous (p = 0.63, I 2 = 0%).
Across 13 studies where both duration of delirium and mortality were reported ( Fig. 4) , meta-regression revealed that delirium duration was not associated with a statistically significant reduced short-term mortality, the slope of the ln(RR mortality) = -0.17 (95% CI -0.39, 0.04; p = 0.11). There was no residual heterogeneity for this association (I 2 = 0%). Because the study by van Eijk et al (46) found a relatively large increase in delirium duration with an intervention meant to decrease delirium duration, we ran a sensitivity analysis of the meta-regression without this study. The relationship between delirium duration and short-term mortality was not substantially changed and remained nonsignificant, the slope of the ln(RR mortality) = -0.10 (95% CI -0.34, 0.15; p = 0.40).
Sensitivity Analyses
The results of the six sensitivity analyses are presented in Table  3 . There was no evidence that either the outcomes duration of delirium or short-term mortality or the association between the two was different for any of the tested subgroups.
DISCUSSION
This systematic review and meta-analysis is the first to summarize published randomized trials evaluating an intervention in critically ill adults hypothesized to reduce delirium burden. Our analyses confirm that pharmacologic and nonpharmacologic interventions in the ICU can reduce delirium duration. However, current RCT data fail to support that a treatment that reduces delirium duration is associated with a reduction in short-term mortality. Analyses within large trials or patient-level meta-analysis across studies are needed to establish this association.
Our findings appear to differ with the results of a recently published meta-analysis and three published cohort studies (16) (17) (18) 51) . The meta-analysis of 14 ICU observational studies involving 5,891 patients found that patients who developed delirium had a higher mortality rate than patients who did not (odds ratio, 3.22; 95% CI, 2.30-4.52) (51). However, this meta-analysis did not consider delirium duration and thus conclusions about the association between delirium duration and mortality cannot be made. The three cohort analyses used regression techniques to demonstrate that a significant relationship between delirium duration and mortality exists at 28 days (18), 6 months (16), and 1 year (17) . The first analysis of 275 mechanically ventilated ICU patients found that each additional day spent in delirium was associated with a 10% increased risk of death at 6 months (hazard ratio [HR], 1.1; 95% CI, 1.0-1.3; p = 0.03) (16) . The second analysis of 304 medical ICU patients who are 60 years old or older revealed that the number of days spent in delirium was significantly associated with greater 1-year mortality (HR, 1.10; 95% CI, 1.02-1.18) (17) . A third analysis of 354 patients enrolled in the Safety and Efficacy of Dexmedetomidine Compared With Midazolam study found that delirium duration was the strongest predictor of 30-day mortality (p < 0.001) among eight different covariates that were modeled and that a dose-response increase in mortality was seen with increasing durations of delirium (18) .
Our results, and how they contrast with the above meta-analysis and cohort analyses, raise a number of important questions. Delirium duration may not be a direct cause of death in the ICU; other factors such as severity of illness may influence delirium prevalence, delirium duration, and short-term mortality (52, 53) . The relationship between delirium duration and mortality 
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Overall may vary by the specific delirium-reducing intervention evaluated. Current clinical trials may be too small to identify a relationship between delirium duration and short-term mortality. Delirium may not always have been accurately recognized in the studies included (54) . Only one screening method, the CAM-ICU, has been used in studies showing an association between delirium duration and mortality (16) (17) (18) . Recent data have suggested that sedation may confound CAM-ICU assessments, and delirium screening with CAM-ICU or ICDSC may not be similar (55) (56) (57) (58) . This is important given that the method of delirium assessment was found to account for the heterogeneity between studies in the meta-analysis by Zhang et al (51) that associated delirium presence with great mortality. Sedation-induced coma is an independent predictor of ICU and hospital mortality in several studies (59) (60) (61) . It is possible that confounding factors within and between studies, including the wide variability in the baseline prevalence of delirium and the nature of different interventions that also influence coma prevalence, may have influenced our results (62) . Future studies evaluating the association between delirium duration and mortality should incorporate coma as an independent outcome. There are important limitations to the data included in the review. We restricted our search to English language studies, did not search the gray literature, and were not able to obtain duration of delirium data from two authors. Although 13 published randomized trials have evaluated the effect of interventions to reduce delirium in the ICU on duration of delirium and death, these studies were highly clinically heterogeneous. Specific statistical techniques (e.g., sensitivity analysis) were thus required. This heterogeneity among the included studies we included may have masked different effects of specific interventions on the duration of delirium and its relationship with mortality. Furthermore, since each intervention was evaluated only within one or two trials, we could not assess whether differences across studies were due to chance or real differences. Thus, our main analyses evaluated the effect of the category of "delirium-reducing interventions" rather than any specific intervention.
Severity of Illness at
Since our primary question of interest was whether interventions that are more effective at reducing delirium duration are also more effective at reducing mortality, not the effect on delirium duration per se on mortality, we believe that the meta-regression of the association is informative in its suggestion of a lack of association between reduction in delirium duration and short-term mortality. Multivariate metaanalysis would have been a preferable analysis to explore the simultaneous treatment effects on the two outcomes. Since this algorithm failed to converge, the meta-regression constituted a reasonable alternative analysis. The individual studies included in our systematic review were generally underpowered to assess short-term mortality, resulting in rare events in many studies and wide CIs for the RR of death. This lack of heterogeneity in treatment effect on mortality may also largely explain the lack of heterogeneity in the meta-regression of delirium duration and death and thus reduced the likelihood of our finding a relationship between these two outcomes.
Another concern is the possibility of publication or reporting bias, wherein unpublished studies (or results) are systematically different than available evidence. We aimed to minimize the reporting bias by contacting authors of studies with missing data. We successfully retrieved both delirium duration and mortality data for 13 of 17 trials (two missing duration data and two missing mortality data). We found no reason to suspect that data were omitted in a biased manner. We also found no reason to suspect that unpublished studies would indicate a different association between delirium duration and mortality. Although our analysis suggests that treatments effective at reducing delirium duration may also not reduce shortterm mortality, appropriate analyses within (existing or new) RCTs that are adequately powered to test for mortality are needed to further evaluate this relationship. This meta-regression across studies can only be hypothesis generating and speaks only to an association, not causation, between the outcomes. Although multivariate metaanalysis would have been a preferable meta-analysis tool, results from such an analysis would still be only hypothesis generating. Within study (or patient-level meta-analyses) are needed for more definitive conclusions.
Duration of delirium may be related to other factors such as changing severity of illness, . Scatter plot of difference in duration of delirium versus risk ratio (RR) for death. Each circle represents a unique study that reported both the difference between treatments in duration of delirium and the RR for death. The size of the circles indicates the weight of each study in the random effects model metaregression. The solid line describes the random effects model meta-regression association across all studies of difference in duration of delirium versus RR death (p = 0.11). The dashed line describes the association excluding the study where the intervention resulted in a longer duration of delirium than the control) (46) (p = 0.40). The equation for each meta-regression line is provided for the logarithm of RR against delirium duration.
the use (or avoidance) of ICU interventions that may influence mortality, or practice misalignment between intervention and controls groups (1, 63, 64) . If an intervention reduces delirium but not the underlying severity of illness, that intervention may not improve mortality. Furthermore, although the APACHE II score was used to define severity of illness in each study, it is a poor predictor of mortality in current ICU practice (65) . Severity of illness may influence both delirium prevalence and mortality; once delirium has occurred, use of interventions to decrease delirium duration may not influence short-term mortality. Finally, given that a number of recent studies have demonstrated that an association exists between delirium duration and longer term brain dysfunction, and generated substantial debate and discussion, future studies evaluating an intervention that may reduce delirium duration should incorporate an assessment of longer term cognitive outcomes (2-4, 10, 66-70).
CONCLUSION
Among RCTs evaluating interventions hypothesized to reduce delirium burden in the ICU, delirium duration is reduced, but our analysis suggests that these treatments may not be associated with reduced short-term mortality. To better answer this 
